A carregar...
Phase I Study of Sunitinib and Irinotecan for Patients with Recurrent Malignant Glioma
BACKGROUND: We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma patients. METHODS: For each 42-day cycle, sunitinib w...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3748953/ https://ncbi.nlm.nih.gov/pubmed/21744079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0631-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|